Methodological consensus on clinical proton MRS of the brain: Review and recommendations by Wilson, Martin et al.
Western University 
Scholarship@Western 
Medical Biophysics Publications Medical Biophysics Department 
8-1-2019 
Methodological consensus on clinical proton MRS of the brain: 
Review and recommendations 
Martin Wilson 
University of Birmingham 
Ovidiu Andronesi 
Harvard Medical School 
Peter B. Barker 
Johns Hopkins School of Medicine 
Robert Bartha 
Robarts Research Institute 
Alberto Bizzi 
Foundation IRCCS Neurological Institute "C. Besta" 
See next page for additional authors 
Follow this and additional works at: https://ir.lib.uwo.ca/biophysicspub 
 Part of the Medical Biophysics Commons 
Citation of this paper: 
Wilson, M, Andronesi, O, Barker, PB, et al. Methodological consensus on clinical proton MRS of the brain: 
Review and recommendations. Magn Reson Med. 2019; 82: 527– 550. https://doi.org/10.1002/
mrm.27742 
Authors 
Martin Wilson, Ovidiu Andronesi, Peter B. Barker, Robert Bartha, Alberto Bizzi, Patrick J. Bolan, Kevin M. 
Brindle, In Young Choi, Cristina Cudalbu, Ulrike Dydak, Uzay E. Emir, Ramon G. Gonzalez, Stephan Gruber, 
Rolf Gruetter, Rakesh K. Gupta, Arend Heerschap, Anke Henning, Hoby P. Hetherington, Petra S. Huppi, 
Ralph E. Hurd, Kejal Kantarci, Risto A. Kauppinen, Dennis W.J. Klomp, Roland Kreis, Marijn J. Kruiskamp, 
Martin O. Leach, Alexander P. Lin, Peter R. Luijten, Małgorzata Marjańska, Andrew A. Maudsley, Dieter J. 
Meyerhoff, and Carolyn E. Mountford 
This article is available at Scholarship@Western: https://ir.lib.uwo.ca/biophysicspub/396 
Magn Reson Med. 2019;82:527–550. wileyonlinelibrary.com/journal/mrm © 2019 International Society for Magnetic Resonance in Medicine  | 527
Received: 28 September 2018 | Revised: 1 February 2019 | Accepted: 25 February 2019
DOI: 10.1002/mrm.27742  
R E V I E W
Methodological consensus on clinical proton MRS of the brain: 
Review and recommendations
Martin Wilson1  |   Ovidiu Andronesi2 |   Peter B. Barker3 |   Robert Bartha4 |   
Alberto Bizzi5 |   Patrick J. Bolan6 |   Kevin M. Brindle7 |   In‐Young Choi8 |   
Cristina Cudalbu9 |   Ulrike Dydak10 |   Uzay E. Emir10 |   Ramon G. Gonzalez11 |   
Stephan Gruber12 |   Rolf Gruetter13 |   Rakesh K. Gupta14 |   Arend Heerschap15 |   
Anke Henning16 |   Hoby P. Hetherington17 |   Petra S. Huppi18 |   Ralph E. Hurd19 |   
Kejal Kantarci20 |   Risto A Kauppinen21 |   Dennis W. J. Klomp22 |   Roland Kreis23  |   
Marijn J. Kruiskamp24 |   Martin O. Leach25 |   Alexander P. Lin26 |   Peter R. Luijten22 |   
Małgorzata Marjańska6 |   Andrew A. Maudsley27  |   Dieter J. Meyerhoff28 |    
Carolyn E. Mountford29 |   Paul G. Mullins30 |   James B. Murdoch31 |   Sarah J. Nelson32 |   
Ralph Noeske33 |   Gülin Öz6 |   Julie W. Pan34 |   Andrew C. Peet35 |   Harish Poptani36 |   
Stefan Posse37 |   Eva‐Maria Ratai2 |   Nouha Salibi38 |   Tom W. J. Scheenen15 |    
Ian C. P. Smith39 |   Brian J. Soher40 |   Ivan Tkáč6 |   Daniel B. Vigneron32 |    
Franklyn A. Howe41
1Centre for Human Brain Health and School of Psychology, University of Birmingham, Birmingham, England
2Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
3Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland
4Robarts Research Institute, University of Western Ontario, London, Canada
5U.O. Neuroradiologia, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
6Department of Radiology, Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, Minnesota
7Department of Biochemistry, University of Cambridge, Cambridge, England
8Department of Neurology, Hoglund Brain Imaging Center, University of Kansas Medical Center, Kansas City, Kansas
9Center for Biomedical Imaging, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland
10School of Health Sciences, Purdue University, West Lafayette, Indiana
11Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
12High Field MR Center, Department of Biomedical imaging and Image‐Guided Therapy, Medical University of Vienna, Vienna, Austria
13Laboratory for Functional and Metabolic Imaging, Center for Biomedical Imaging, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland
14Fortis Memorial Research Institute, Gurugram, Haryana, India
15Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
16Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
17Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania
18Department of Pediatrics, University of Geneva, Geneva, Switzerland
19Stanford Radiological Sciences Lab, Stanford, California
20Department of Radiology, Mayo Clinic, Rochester, Minnesota
21School of Psychological Science, University of Bristol, Bristol, England
528 |   WILSON et aL.
22University Medical Centre Utrecht, Utrecht, the Netherlands
23Departments of Radiology and Biomedical Research, University of Bern, Bern, Switzerland
24Philips Healthcare, Best, the Netherlands
25CRUK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden Hospital, London, England
26Center for Clinical Spectroscopy, Brigham and Women’s Hospital, Harvard University Medical School, Boston, Massachusetts
27Department of Radiology, University of Miami, Miami, Florida
28DVA Medical Center and Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
29Translational Research Institute, Woolloongabba, Australia
30Bangor Imaging Unit, School of Psychology, Bangor University, Bangor, Wales
31Canon Medical Research USA, Mayfield Village, Ohio
32Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
33GE Healthcare, Berlin, Germany
34Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania
35Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, England
36Centre for Preclinical Imaging, Institute of Translational Medicine, University of Liverpool, Liverpool, England
37Department of Neurology, University of New Mexico, Albuquerque, New Mexico
38MR R&D, Siemens Healthineers, Malvern, Pennsylvania
39Innovative Biodiagnostics, Winnipeg, Canada
40Department of Radiology, Duke University Medical Center, Durham, North Carolina
41Molecular and Clinical Sciences, St George’s University of London, London, England
Correspondence
Martin Wilson, Centre for Human Brain 
Health, University of Birmingham, 




Proton MRS (1H MRS) provides noninvasive, quantitative metabolite profiles of 
tissue and has been shown to aid the clinical management of several brain diseases. 
Although most modern clinical MR scanners support MRS capabilities, routine use is 
largely restricted to specialized centers with good access to MR research support. 
Widespread adoption has been slow for several reasons, and technical challenges 
toward obtaining reliable good‐quality results have been identified as a contributing fac-
tor. Considerable progress has been made by the research community to address many of 
these challenges, and in this paper a consensus is presented on deficiencies in widely 
available MRS methodology and validated improvements that are currently in routine 
use at several clinical research institutions. In particular, the localization error for the 
PRESS localization sequence was found to be unacceptably high at 3 T, and use of the 
semi‐adiabatic localization by adiabatic selective refocusing sequence is a recommended 
solution. Incorporation of simulated metabolite basis sets into analysis routines is recom-
mended for reliably capturing the full spectral detail available from short TE acquisi-
tions. In addition, the importance of achieving a highly homogenous static magnetic field 
(B0) in the acquisition region is emphasized, and the limitations of current methods and 
hardware are discussed. Most recommendations require only software improvements, 
greatly enhancing the capabilities of clinical MRS on existing hardware. Implementation 
of these recommendations should strengthen current clinical applications and advance 
progress toward developing and validating new MRS biomarkers for clinical use.
K E Y W O R D S
brain, consensus, metabolites, MRS, semi‐LASER, shimming
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1 |  INTRODUCTION
Proton MRS (1H MRS) has provided a noninvasive measure 
of brain metabolites since the late 1980s. Abnormal metab-
olism is often closely linked to disease processes; therefore, 
MRS may improve clinical diagnosis, treatment effect moni-
toring, and understanding of disease mechanisms.1 However, 
widespread clinical adoption has been slow, with MRS being 
used primarily in specialized imaging centers.
Increased availability of 3T MR scanners in hospitals 
presents an important opportunity for MRS, as metabo-
lite levels are more reliably measured than at 1.5 T due to 
reduced spectral overlap and an improved SNR (Figure 1).2 
However, additional challenges are associated with 3T 
MRS compared with 1.5 T. Reduced homogeneity of the 
static magnetic field (B0) at 3 T results in broadened spec-
tral linewidths and degraded spectral quality; therefore, 
improvements in hardware and methodology for optimizing 
the B0 homogeneity over the region for MRS are necessary. 
Metabolite localization errors, known as chemical shift dis-
placement (CSD), also increase at 3 T, requiring optimized 
RF pulse shapes and higher B1 RF power to compensate. 
Recent progress in the research community has addressed 
these challenges, but a major disparity remains between 
what is available for research and for routine clinical appli-
cations. In addition, the wide range of MRS sequences, 
parameters, and analysis choices can make the technique 
particularly difficult for nonexpert users.
This paper was written and agreed upon by 49 MRS 
experts who belong to the International Society for Magnetic 
Resonance in Medicine (ISMRM) MRS study group with the 
following aims:
1. Recommend appropriate methodology to improve the 
quality of future MRS studies and increase MRS stan-
dardization, to facilitate clinical trials and meta‐analyses 
of MRS efficacy;
2. Provide recommendations to vendors regarding the best 
MRS implementations and practices; and
3. Focus the research community on resolving key technical 
barriers that have delayed wider clinical adoption of MRS.
Following initial discussions, an online survey was 
designed and completed by the group, and the results 
(Supporting Information Section A) were used to guide fur-
ther discussions leading to our final consensus and recom-
mendations. We restricted our scope to 1H MRS detection 
of endogenous brain metabolites, using currently available 
methodologies that we believe are ready for incorporation 
into clinical scanner platforms. We first present a basic 
introduction to 1H MRS methodology that is designed 
to give newcomers to 1H MRS sufficient background to 
understand the subsequent consensus sections.
2 |  STANDARD MRS 
METHODOLOGY
2.1 | Single‐voxel spectroscopy
Proton single‐voxel spectroscopy (SVS) is relatively simple 
to plan and yields clinically informative results, with robust 
acquisition procedures available on all commercial systems. 
Single‐voxel spectroscopy is currently the most commonly 
used method to acquire spectra from a single volume of 
F I G U R E  1  An adult low‐grade glioma brain tumor spectrum 
acquired at 3 T with PRESS single‐voxel spectroscopy (SVS) 
localization, 18‐mm‐sided cubic voxel, 128 averages, TE = 32 ms, 
and TR = 2 seconds. Parametric fitting was performed with the 
TARQUIN algorithm35 using a simulated basis set of metabolite, 
lipid, and macromolecule signals. Although a greater level of spectral 
detail is available when compared with 1.5 T, particularly for strongly 
J‐coupled metabolites such as glutamate and myo‐inositol, data quality 
is highly dependent on achieving good shimming. For this example, 
a metabolite FWHM of 0.03 ppm and SNR of 83 were achieved, in 
which the FWHM was measured from the highest metabolite signal 
(total choline [tCho] = glycerophosphocholine + phosphorylcholine) 
following baseline subtraction. The SNR was calculated as the ratio 
between the highest baseline subtracted, metabolite signal intensity, 
and 2 times the SD of the noise level estimated from a spectral region 
free from metabolite signals
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interest (VOI or voxel). Generally, a 5‐minute acquisition 
time provides good‐quality spectra at 3 T from tissue vol-
umes down to 4 cm3, assuming that good B0 homogeneity 
can be achieved. We briefly outline the main technical con-
siderations for widely available SVS methodology.
2.1.1 | Acquisition methods
Stimulated echo acquisition mode (STEAM)3,4 and point‐
resolved spectroscopy (PRESS)5 are used widely to pro-
vide single‐shot 3D localization from the intersection of 3 
slices. In STEAM, 3 slice‐selective RF pulses, each with 
90° flip angles, produce a stimulated echo with typically a 
shortest TE of approximately 20 ms. In PRESS, a 90° exci-
tation pulse combined with 2 refocusing pulses produce a 
spin echo with a shortest TE of approximately 30 ms. The 
PRESS refocusing pulses are nominally 180°; however, 
some implementations use lower flip angles. Shorter TEs 
are possible for both STEAM and PRESS, but we restrict 
this section to commercial implementations. The PRESS 
technique is more commonly used, as its spin echo pro-
vides twice the signal compared with the STEAM stimu-
lated echo.
Because multiple averages are typically measured for 
SVS, the phase of the RF pulses and receiver may be cycled 
between averages to suppress artifacts from outer‐volume sig-
nals, imperfect flip angles, and imbalances in scanner elec-
tronics—a method known as phase cycling.6,7 Phase cycling 
schemes are typically applied in blocks of 2, 4, 8, or 16 aver-
ages, which are repeated to attain the desired scan duration. 
A further method to reduce artifacts originating from outside 
the prescribed voxel is to ensure that the last slice‐selection 
plane is perpendicular to regions of B0 inhomogeneity. For 
example, having the final slice‐selection plane in the axial 
direction has been shown to reduce SVS artifacts in frontal 
brain regions by eliminating spurious signals caused by B0 
inhomogeneity in the mouth and sinuses.7,8
All localization methods based on RF/gradient slice 
selection, such as PRESS and STEAM, exhibit a localiza-
tion inaccuracy known as the chemical shift displacement 
(CSD) error. The CSD error causes a spatial displacement 
of metabolite resonance localization, in which resonances 
further from the center frequency of the RF pulse are dis-
placed to a greater extent (Figure 2). Metabolites with 
frequency‐separated J‐coupled multiplets, such as lactate, 
may have reduced signal due to regions around the voxel 
edge periphery not experiencing all 3 localization pulses 
equally.9 For a given maximum RF amplitude (B1max), 
the CSD error worsens with increasing field strength and 
reduced RF pulse bandwidth. Therefore, CSD is worse 
for PRESS than STEAM, as conventional 90° pulses have 
greater bandwidth than conventional 180° pulses for a fixed 
pulse duration and B1max. The CSD severity and reduction 
will be described in the “Consensus opinion and recom-
mendations” section.
In recent years, the development of the phased‐array head 
coil10,11 has resulted in improved SNR for MRI and MRS, 
and modern vendor‐supplied MRS protocols at 1.5 T and 3 T 
are performed using the body (volume) coil for B1 transmis-
sion and a phased‐array head coil for B1 reception. Compared 
with traditional transmit–receive (T/R) birdcage head coils, 
the combination of phased‐arrayed receive and volume trans-
mit offers improved SNR in cortical brain regions, due to the 
close proximity of receive coils to cortical areas, and homo-
geneous B1 available from the volume transmit coil. In cen-
tral brain regions, SNR gains are feasible using tighter‐fitting 
receive coils. For well‐designed coils and optimized data 
reconstruction,12-14 a higher number of array elements should 
confer improved SNR in cortical regions, with a recent report 
demonstrating a 40% improvement when using 32 elements 
compared with 8.15 One potential disadvantage with using 
body coils for transmission is reduced B1max when compared 
with T/R designs; however, adequate B1max has been demon-
strated at 3 T for low CSD sequences (see “Single‐voxel 
spectroscopy acquisition consensus” section). Overall, the 
use of phased‐array head coils with a high number of receive 
elements is recommended for neuro SVS and MRS imaging 
(MRSI) at 1.5 T and 3 T.
2.1.2 | Repetition time and TE 
considerations
Proper determination of absolute metabolite concentrations 
or ratios (e.g., total N‐acetylaspartate [tNAA]/total creatine 
[tCr]) ideally requires long TRs and short TEs to minimize 
signal loss from T1 saturation and T2 relaxation effects, 
respectively. Short TEs (20‐30 ms) also offer improved 
detection of metabolites with complex J‐coupled spectral 
patterns (e.g., glutamine, glutamate, and myo‐inositol) due 
to reduced dephasing from J‐coupling evolution. High‐qual-
ity short‐TE MRS allows the quantification of an extended 
neurochemical profile, including neurotransmitters and anti-
oxidants.16 However, a challenge associated with shorter 
TEs is the enhancement of broad short‐T2 signals from 
high‐molecular‐weight macromolecules (MMs) and lipids.17 
Appropriate analysis methods are capable of separating 
metabolite and lipid/MM signals, but poor B0 homogeneity 
degrades this separation; longer TE acquisitions may be used 
to suppress broad MM and lipid signals, and simultaneously 
refocus weakly J‐coupled spins. For instance, a TE of 144 
ms or 288 ms is used commonly to aid the discrimination 
of lactate from lipids and singlets from overlapping multi-
plets. Although long TRs (> 2 seconds) reduce unwanted 
signal loss per transient/average from T1 relaxation effects, 
the metabolite SNR per unit time is also reduced; therefore, a 
compromise is often required for clinical MRS.
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F I G U R E  2  Comparison of vendor‐supplied MRS implementation of PRESS versus an advanced in‐house protocol using semi‐LASER79 
and improved water suppression, shimming, and data processing on a 3T MRI system. Spectra (TE = 30 ms, TR = 5 seconds, 64 transients) were 
acquired from the same voxel in the cerebellar vermis of a healthy volunteer. A, Water was suppressed by about 150 fold by the chemical shift–
selective sequence in the PRESS protocol and about 4500 fold by the variable pulse power and optimized relaxation delays scheme29 incorporated 
into the semi‐LASER sequence. B, Chemical shift displacement (CSD) for resonances with a chemical shift difference of 3 ppm is 36%‐39% with 
the PRESS sequence versus 6% with the semi‐LASER sequence in the 2 dimensions shown. C, Narrower linewidths (shown for the total creatine 
[tCr] signal) are obtained with FASTMAP shimming18 in conjunction with single‐shot frequency and phase correction in the semi‐LASER protocol 
versus product shimming and signal averaging in the PRESS protocol in the absence of motion during scanning. D, A small amount of motion 
(few degrees in z such that the cerebellar volume of interest [VOI] was still acceptable at the extremes of motion) further degrades the linewidths 
and generates unwanted coherences that are not removed with phase cycling in the PRESS protocol (highlighted by the circle). In contrast, spectral 
quality is unchanged, with an acceptable water residual in the semi‐LASER protocol thanks to artifact‐free single shots and frequency and phase 
correction of individual shots
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2.1.3 | B0 inhomogeneity
In vivo susceptibility‐induced magnetic field distortions 
arise from the presence of air/tissue and tissue/bone inter-
faces. In brain, field distortions are most apparent in regions 
close to sinuses, such as the prefrontal cortex and temporal 
lobes, and because susceptibility differences scale with the 
static field strength, these distortions are stronger at higher 
fields. A homogenous static magnetic field, B0, is essential 
for MRS, as narrow linewidths provide the spectral resolu-
tion that is critical for observation of multiplet resonances, 
accurate metabolite quantification, and efficient water sup-
pression. In addition to gradient coils, MR systems incor-
porate shim coils to compensate for B0 inhomogeneity, and 
adjustment of currents flowing through these coils is called 
“shimming.”
Vendor‐provided shimming routines are currently based 
on the acquisition of a 3D B0 field map (GRESHIM), B0 field 
mapping along orthogonal projections (FASTMAP and its 
variants),18-22 or along orthogonal planes of the localization 
VOI. The B0 field variations calculated from signal‐phase 
differences are used to compute the currents needed for each 
of the available shim coils.23-25 The B0 field distortions over 
typical SVS dimensions are generally compensated using a 
first‐order shim (using the linear x, y, and z imaging gradient 
coils) at 1.5 T, whereas the use of second‐order shim ele-
ments terms (z2, x2‐y2, x‐y, x‐z, and y‐z) is strongly recom-
mended for SVS at 3 T.26
2.1.4 | Water suppression
Detection of millimolar metabolite signals in the presence 
of 3‐4 orders of magnitude higher water (~40 M) signals 
is challenging due to the spectral baseline interference 
originating from the tails of the large water resonance. In 
addition, water “sideband” distortions, originating from 
various sources including subject movement, as well as 
mechanical vibration and instability of RF and gradient 
electronics, produce spurious signals that further confound 
metabolite signal estimates. Such interferences can be miti-
gated during acquisition by using a water‐suppression mod-
ule before the MRS localization module. The most common 
methods exploit the chemical shift difference between 
water (4.65 ppm) and the strongest metabolite resonances 
(4.2‐0.8 ppm). Common methods include repeated chemi-
cal shift–selective saturation pulses at the frequency of 
water27; water suppression enhanced through T1 effects
28; 
and variable pulse power and optimized relaxation delays29 
(Figure 2). In general, the effectiveness of water sup-
pression is significantly affected by B0 homogeneity, as 
methods require narrow‐bandwidth frequency‐selective 
pulses to avoid inadvertent suppression of metabolite reso-
nances closest to the water resonance.
2.1.5 | Voxel dimensions and placement
In nonfocal diffuse brain disease or general physiological 
studies, the SVS acquisition voxel is preferentially placed 
far away from air/tissue interfaces, because of shimming 
difficulties, and away from the scalp to prevent spurious 
out‐of‐volume lipid signals. In a 5‐minute acquisition time, 
an 8‐cm3 cuboid volume in parieto‐occipital gray matter or 
parietal white matter provides high‐quality spectra at 1.5 T. 
Smaller volumes down to 4 cm3 also yield spectra that allow 
metabolite quantification beyond tNAA, tCr, and total cho-
line (tCho) at 3 T within 5 minutes, provided that good B0 
homogeneity can be achieved. In focal diseases or specific 
anatomical areas of interest, voxels that best fit the targeted 
anatomy or lesion are commonly used. Contamination by 
lipid signals occurs for voxels located too close to the scalp, 
and trial voxel placement in volunteers to assess slice‐profile 
and CSD limitations experimentally is advised. In addition to 
careful voxel positioning, outer‐volume suppression (OVS) 
may be used to suppress signal from unwanted regions in 
challenging areas. In general, volumes below 4 cm3 do not 
have an adequate SNR if detailed metabolic profiles are 
needed to answer clinical questions within a reasonable 
5‐minute acquisition time, but may be acceptable for restricted 
analysis such as the tCho/tNAA ratio in brain tumors. Voxel 
volumes greater than 8 cm3 or prolonged scan times are 
needed to detect small changes in low‐SNR metabolites such 
as glutathione, and aid the discrimination between heavily 
overlapped multiplets such as glutamate and glutamine.
2.1.6 | Data analysis
Gross spectral features are amenable to expert visual inter-
pretation (e.g., lipids that indicate a high‐grade tumor30); 
however, automated analyses of metabolite signals provide 
objective measures, such as relative metabolite concentra-
tions or ratios, as biomarkers for clinical decision mak-
ing and clinical trials.31 Magnetic resonance spectroscopy 
analysis using basis sets of known metabolites, MM and 
lipid signals parametrically fitted to the data with modeling 
of baseline and peak line‐shape variations, have been par-
ticularly successful (Figure 1). Fitting may be performed in 
the frequency domain, where baseline distortions may be 
modeled as smoothly varying spline functions (LCModel32) 
or decomposed using wavelets (VeSPA33). Time‐domain 
analysis may also be used to reduce errors from baseline 
signals by omitting initial data points from the fit, exploiting 
the rapid temporal decay of baseline distortions (QUEST34, 
TARQUIN35). Metabolite basis sets can be acquired experi-
mentally or simulated from known parameters,36-38 and 
either approach is effective.39,40 The addition of known 
MM and lipid signals to the basis set results in improved 
analysis, particularly for short‐TE data sets or tumor spectral 
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analyses.41 B0 inhomogeneity and artifacts originating 
from rapidly changing gradients, known as eddy currents, 
broaden and distort the MRS line shape from its ideal form 
(e.g., Lorentzian for singlet peaks). For accurate analyses, 
these line‐shape variations should be reduced by correc-
tion based on the unsuppressed tissue water signal42 and/or 
 modeled during the fitting algorithm.32
2.1.7 | Data quality
Quality control requires consideration of (1) SNR, (2) 
metabolite and unsuppressed water resonance linewidths, (3) 
residual water signal, (4) line shape, (5) Cramér‐Rao lower 
bounds (CRLBs) of the data fit, (6) fit quality (relative size 
of residuals versus noise SD), and (7) presence of artifacts 
(spurious signals, baseline distortions, contamination from 
subcutaneous lipids). The first 6 can be calculated automati-
cally by spectral analysis software; however, the evaluation 
of artifacts currently necessitates inspection by an experi-
enced reader of MRS.43 Current automatic quality control 
suffers from a lack of evidence‐based quality thresholds, 
although general recommendations are available.1,44,45 An 
accepted numerical quality estimate in relation to model 
fitting of MRS data is the CRLB: a lower estimate of the 
error of the concentration measurement as influenced by 
SNR, linewidth, and mutual signal overlap. A relative CRLB 
greater than 50% indicates that there is insufficient informa-
tion to claim that the estimated value is significantly different 
from zero; therefore, it is often considered to be unreliable. 
However, it may also indicate that the estimated value is too 
low to be reliably measured, which may be clinically sig-
nificant.46 Influences from artifacts are not included in the 
CRLB calculation, and these are illustrated and discussed in 
Supporting Information Figures S1, S2, and Section B.
2.1.8 | Absolute quantitation methodology
The obtained MR signal is proportional to the number of con-
tributing 1H nuclei in the VOI, but the signal is not calibrated 
and measurement of absolute metabolite concentration is 
challenging due to unknown scaling factors such as receiver 
coil sensitivity and loading. For metabolite ratios, these fac-
tors cancel, and for this reason metabolite ratios (e.g., tNAA/
tCr) are widely reported for clinical use, despite the ambigu-
ity of attributing changes to the metabolite in the numera-
tor or denominator. Additionally, small or inaccurate values 
for the denominator produce large variance in a metabolite 
ratio. Semiquantitative MRS can be obtained from the ratio 
of each metabolite to the unsuppressed tissue water signal 
from the same VOI and using an assumed MR visible tissue 
water content.47 Full concentration quantitation requires cor-
rection of water and metabolite signals for relaxation factors, 
assessment of any tissue partial volume effects (e.g., relative 
proportions of gray and white matter, CSF, or pathological 
tissue in the VOI), and correction for disease‐induced water 
concentration alterations.48 One challenge with concentration 
measures is that accurate knowledge of water and metabolite 
relaxation times are required, which may not be available for 
pathological tissue (see Supporting Information Section C 
for a discussion on relaxation‐time effects on quantitation). 
In principle, using TEs shorter than 15 ms minimizes abso-
lute quantitation errors of singlet peaks to less than 10% and 
reduces the dependence on assumed T2 relaxation values; 
however, technical challenges with accurate localization at 
very short TE make this impractical with currently available 
commercial MRS sequences.
2.2 | Magnetic resonance 
spectroscopic imaging
Although SVS is appropriate for investigation of a focal 
lesion, a specific anatomical region, or diffuse brain disease, 
MRSI is preferred when the location of interest is uncertain 
or multiple areas need to be evaluated simultaneously, such 
as when investigating metabolite distributions across hetero-
geneous lesions due to a tumor. In its most commonly used 
implementation at 3 T, a 16 × 16 grid of spectra with nomi-
nal voxel resolution of 1.5 cm3 may be acquired in approxi-
mately 5 minutes at a TR of 1500 ms, with 1 average per 
phase‐encoding step and elliptical k‐space sampling. Despite 
the advantage of spatial metabolite information offered by 
2D and 3D MRSI, robust acquisitions of good‐quality data 
present significant challenges. Practical issues include achiev-
ing adequate B0 homogeneity over a large volume for good 
spectral resolution and reliable water suppression, good scalp 
lipid suppression, and automated and accurate analysis of large 
multivoxel data sets and their presentation for intuitive inter-
pretation. In the following sections, we briefly introduce the 
technical issues surrounding MRSI acquisition and analysis.
2.2.1 | Localization and phase encoding
Contrary to a small voxel that is selected in SVS, in MRSI 
a larger volume is selected to acquire signals from multiple 
voxels across a 2D or 3D grid. This volume can be a slice 
through the brain, acquired using single slice‐selective exci-
tation and refocusing pulses combined with OVS slices to 
suppress scalp lipid. A single 2D slice or 3D cubic volume 
can be selected with orthogonal slice‐localization methods 
such as PRESS or STEAM as described for SVS. Within 
the selected slice or volume, 2D or 3D phase encoding is 
performed to localize spectral signals to a specific grid loca-
tion. Outer‐volume suppression is essential in slice‐localized 
acquisitions to suppress subcutaneous lipid signals, and may 
be used in combination with PRESS or STEAM localization 
to reduce spurious outer‐volume and scalp lipid signals. The 
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OVS slices are also used to create a target VOI that better 
conforms to the brain shape and a relevant tissue region, as 
well as aid in the optimization of shimming and water sup-
pression over a more restricted region (Figure 3).
Although the CSD, which is expressed as the displacement/
ppm as a percentage of the localization width (%CSD), remains 
constant for a particular sequence, absolute CSD increases pro-
portionally with the prelocalization dimensions. Therefore, 
increased in‐plane CSD is a significant problem for MRSI, in 
which localization volumes are much larger compared with 
SVS. Typical 2D MRSI PRESS implementations at 3 T have 
an in‐plane %CSD of over 10%/ppm, resulting in a relative 
displacement of 1.2 cm between tCho and tNAA localization 
volumes for a 10 × 10 × 1 cm3 axial PRESS volume, in both 
the left–right and anterior–posterior directions (Figure 4).
The phase‐encoding localization method is based on 
the incremental adjustment of the strength of an applied 
magnetic gradient field and may be applied to MRS acquisi-
tions to create a “spectroscopic” image.49,50 Unlike slice local-
ization described previously, localization by phase encoding 
does not exhibit CSD effects or geometrical distortions due 
to B0 inhomogeneity, and allows relative metabolite signal 
frequencies to be preserved independent of spatial position. 
Although data matrix sizes are small in MRSI compared with 
F I G U R E  3  Three‐dimensional MRS imaging [MRSI] (bottom left: TE = 144 ms, TR = 1.25 seconds; bottom right: TE = 35 ms, TR = 1.3 
seconds) acquired at 3 T from a patient with glioblastoma. Both scans had a nominal voxel resolution of 1 cm3, and 4‐Hz spectral apodization was 
applied. The PRESS excitation volume (yellow rectangle) and 8 very selective saturation (VSS) outer suppression bands (shaded purple) are shown 
in the top panel. Both the PRESS volume and VSS outer suppression bands were automatically prescribed using in‐house software.107 Good‐quality 
spectra from the red gridded region (top) of slices close to the center of the PRESS box are highlighted for both long and short TEs (bottom)
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MRI, acquisition times become substantial as spatial reso-
lution increases or if 3D data are required (e.g., > 51 min-
utes for 3D MRSI when acquiring a full 16 × 16 × 8 matrix 
with TR of 1500 ms). To reduce acquisition times, higher 
frequency spatial components are sacrificed by limiting the 
k‐space acquisition to a spherical or elliptical region, instead 
of a rectangular one, which reduces measurement time by 
25% for 2D and 50% for 3D MRSI.
The MRSI acquisition planning and results are typically 
displayed as a grid of voxels, in which the nominal voxel 
dimensions in the phase‐encoded directions are determined 
by the FOV divided by the number of phase‐encoding steps. 
Unlike SVS, in which it can be reasonably assumed that most/
almost all signal originates from the prescribed voxel location, 
MRSI “voxels” may have a significant amount of signal con-
tribution from outside the displayed grid boundaries or nomi-
nal voxel volumes. The point‐spread function (PSF) describes 
precisely how the signal from the surrounding area contributes 
to a location on the MRSI grid. For phase‐encoded MRSI, the 
PSF is a complex sinc function; therefore, the signal within 
a voxel includes positive and negative contributions that 
decrease with distance from the voxel center (Figure 5A,C). 
Scalp lipids are particularly prone to producing signals that are 
localized within the MRSI grid, distant from their true spa-
tial origin (known as signal “bleed”) due to the MRSI PSF. 
These artifacts can often cause significant spectral distortion 
and confound the true estimation of metabolite and lipid levels 
originating from brain tissue.
2.2.2 | Acquisition‐based suppression of 
scalp lipid
Scalp lipid suppression may also be achieved with OVS, 
frequency‐selective saturation, and inversion recovery (IR) 
methods, either in isolation or in combination with PRESS 
or STEAM localization. Outer‐volume suppression is typi-
cally applied using 8 perpendicular planes to the MRSI exci-
tation, arranged in an octagonal pattern around the scalp.51 
Outer‐volume suppression maintains target region signals, 
but is cumbersome to plan and has limited lipid suppression 
efficiency. The IR approach with a non‐frequency‐selective 
adiabatic inversion pulse is relatively insensitive to B1 inho-
mogeneity and eliminates the need for careful OVS prescrip-
tion.52 A drawback of IR lipid suppression, however, is that 
T1 relaxation also occurs for metabolites in the IR period, 
resulting in unwanted metabolite T1 weighting and signal 
loss (approximately 25% at 3 T), which is greater the shorter 
the metabolite T1 is. For many neurological disorders, intrac-
erebral lipids are not of interest; hence, global lipid suppres-
sion using IR is inconsequential. However, lipid signals in 
the target volume are important diagnostically for tumors, 
stroke, and lipid metabolism disorders.
F I G U R E  4  Two‐dimensional PRESS CSI acquired at 3 T in a healthy volunteer using TR = 2000 ms, TE = 32 ms, and elliptical sampling 
from a 20 × 20 k‐space grid with nominal voxel size of 10 × 10 × 10 mm3 and 13‐minute acquisition time (including a reduced spatial‐resolution 
water reference for zero‐order phasing). Spectral data are shown over the range of 0.5 ppm to 4 ppm for the central 10 × 10 voxels, and the 
PRESS localization volume was prescribed as the outer edge of the grid with the transmitter frequency set to the expected frequency of the total 
N‐acetylaspartate (tNAA) resonance at 2.01 ppm. Spectra were analyzed with LCModel, and the metabolite maps are shown in a false color scale 
normalized to a maximum of 1.0. The PRESS volume edge is defined at the zero excitation level (i.e., the lower tNAA signal in all outer voxels). 
There are much greater reductions in tCho and tCr in the top rows and right columns due to CSD relative to tNAA, which was the metabolite set 
on‐resonance for the PRESS localization. Thus, the absolute signal intensity is modulated by the nonuniformity of the PRESS excitation and further 
convolved with the CSD effect when metabolite ratios are used
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2.2.3 | B0 inhomogeneity
Adequate shimming is significantly more difficult for MRSI 
compared with SVS. The B0 inhomogeneity must be cor-
rected over a larger tissue volume, and B0 inhomogeneity 
in regions close to the scalp or sinuses may exacerbate arti-
facts due to PSF effects. Whole‐brain 3D MRSI with first 
and second‐order shimming may have up to 35% of voxels 
with insufficient data quality for analysis at 3 T.53 B0 hetero-
geneity is so large across the whole brain that the required 
shim strength for optimal homogeneity increases by an order 
of magnitude going from a slice above the ventricles to the 
temporal lobe.54 Therefore, the need for adequate shimming 
hardware with second‐order shim coils and associated high‐
power amplifiers, combined with reliable software shimming 
algorithms, is particularly important for MRSI.
2.2.4 | Parallel imaging
For MRSI over large brain volumes, phased‐array head coils 
provide improved sensitivity in cortical brain regions and 
enable the use of parallel reconstruction methods, such as 
SENSE, to improve spatial resolution or reduce scan times. 
Potential artifacts from parallel imaging methods include 
incorrectly localized signals, due to the imperfect reconstruc-
tion, which may not be visually obvious for metabolites in 
low‐spatial‐resolution MRSI data. However, incorrectly 
localized scalp lipids signals are generally more notable,55-57 
which may be shifted in frequency due to B0 inhomogene-
ity and aliased to obscure metabolite peaks. Additional 
challenges in accurate reconstruction are due to metabolite 
signals having a considerably lower concentration, and there-
fore SNR, compared with water. Self‐calibration parallel 
imaging methods, such as GRAPPA, have also been applied 
to MRSI acquisition.58 The full impact of parallel imaging 
methods on MRSI metabolite quantification levels is still 
under investigation.53,59,60
2.2.5 | Postprocessing
With multichannel coil acquisitions, corrections for coil‐
dependent signal strength and phase characteristics for each 
spectrum must be made to combine the data optimally.12-14,61 
An MRSI scan of the unsuppressed water obtained at low 
spatial resolution can aid zero‐order phasing, frequency 
offset, and line‐shape corrections of the metabolite spectra 
without a major time penalty. With phased‐array coils and 
SENSE, a water‐reference signal for metabolite quantitation 
F I G U R E  5  The one‐dimensional point spread function (PSF) for phase‐encoded MRSI with 16 points (A) and with reduced spatial signal 
spread and resolution when applying a Hamming k‐space filter (B). The PSF of the more commonly used 16 × 16 circularly sampled 2D phase‐
encoding scheme for MRSI is illustrated in (C) and the corresponding Hamming‐filtered PSF is shown in (D). A nominal resolution of 1‐cm and 
16‐cm FOV was used for all plots. Due to the PSF and its filtering, the effective voxel size is considerably larger than the nominal voxel size
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may be acquired at the same spatial resolution as the metabo-
lite scan, but with a significantly reduced scan duration as an 
alternative to a low‐resolution acquisition.62
Following recombination of data from the individual coil 
elements, zero‐filling of the k‐space data is often used to 
reduce the apparent voxel size and produce smoother‐look-
ing metabolite maps. However, this step only amounts to 
interpolation and does not reduce the effects of the PSF or 
increase spatial resolution. Spatial filtering is often applied 
to reduce Gibbs ringing artifacts from scalp lipid and from 
truncation artifacts associated with reduced k‐space acqui-
sitions.63 This also causes widening of the central lobe of 
the PSF, resulting in improved spectral SNR, but reduced 
spatial resolution. Figure 5 illustrates the influence of the 
commonly used Hamming filter on the PSF for typical MRSI 
acquisition parameters. Subsequent to processing the MRSI 
data in k‐space, 2D or 3D spatial Fourier transformation is 
applied to generate a series of FIDs for each voxel. These 
may be analyzed in the time or frequency domain with the 
same methods used for SVS, or simply Fourier transformed 
in the chemical shift dimension to create an array of spectra 
for a visual assessment.
2.2.6 | Data analysis and metabolite maps
Two‐dimensional and 3D MRSI produce large amounts of 
data; therefore, robust, automated data processing to gener-
ate metabolite maps is needed for ease of clinical interpreta-
tion. Acquisitions at 3 T with phased‐array head coils have 
greater spatial variation in receive sensitivity than studies 
at 1.5 T with quadrature or birdcage head coil designs, and 
at 3 T dielectric effects can compromise RF transmission 
homogeneity. Hence, using a semiquantitative approach with 
reference to contralateral brain or a coil reference sample 
are problematic. The MRSI metabolite concentrations can 
be calculated if an additional water reference is acquired48; 
however, the associated time penalty may be significant 
(when using conventional methods), as all phase‐encoding 
steps need to be repeated. Metabolite ratio maps can be more 
robust than maps of “absolute” levels (albeit semiquantitative 
if relaxation effects are ignored), as they are less sensitive 
to tissue partial‐volume effects with CSF. However, partial‐
volume effects between tissue types such as gray and white 
matter,64,65 or normal and diseased tissues,66 are important to 
consider when interpreting the data.
2.2.7 | Cautions and quality control
Automatically generated metabolite maps can be unreliable 
due to the effects of poor water suppression, lipid contamina-
tion and B0 inhomogeneity, and they are degraded by subject 
motion and inaccuracies of spectral fitting. Therefore, qual-
ity assessment of individual spectra and their fit is a required 
step for proper interpretation. However, visual quality assess-
ment is often impractical with MRSI, resulting in a need for 
automated methods to exclude poor‐quality data. The relative 
CRLB derived from fitting each spectrum to a model func-
tion is misleading as a numeric estimate of data quality if 
there is a real absence of specific metabolites; however, good 
CRLB values may also arise from fitting bad‐quality spec-
tra if the noise is underestimated, artifacts are present, or the 
fitting method has converged to an incorrect solution (local 
minimum). Alternative quality measures include CRLB val-
ues from a fit to a co‐located water signal, using confidence 
limits67 and linewidths from spectral fitting of metabolites or 
water, detection of outlying values in the spectrum,68 and use 
of pattern recognition to classify poor‐quality spectra.44,69,70 
A quality map enables easy interpretation at the time of the 
clinical read, such as implemented in the MIDAS software71 
(Figure 6). Nevertheless, a visual assessment of spectra in 
key diagnostic locations is still advisable, and a zoomed‐in 
grid of the raw spectra overlaid on the MRI of the abnormal 
region adds confidence to any interpretation of metabolite 
maps.
In addition to poor‐quality data, visual interpretation 
of metabolite maps can present difficulties, particularly at 
the low spatial resolution of MRSI as compared with MRI, 
for which partial‐volume effects can be significant. Highly 
interpolated MRSI data can give a misleading impression of 
spatial detail, and PSF effects reduce the actual spatial res-
olution and may create artifactual “hot” or “cold” spots. B0 
inhomogeneity can cause localized signal loss, which may be 
obvious in temporal–frontal brain regions due to proximity 
to sinuses, but can also occur in areas of blood breakdown 
products or calcification, and close to surgical entry points 
(e.g., craniotomy staples). Finally, maps of metabolite ratios 
can include exceptionally high values because of a division 
by a small metabolite value, and visual inspection is required 
to interpret these regions correctly.
3 |  CONSENSUS OPINION AND 
RECOMMENDATIONS
The following discussion is based on the results of an MRS 
technical consensus survey completed by 35 experts in clini-
cal MRS (Supporting Information Section A) and subse-
quent discussions among all authors. The survey aimed to 
determine what specifically could be recommended as best 
practice using the current standard implementations of 1H 
MRS, and to define current limitations of scanner hard-
ware and software. The survey also indicated the practical 
solutions that have been developed within the research envi-
ronment. Key areas inhibiting the more widespread clinical 
use of MRS are limitations in shimming algorithms, the prac-
ticalities of voxel planning and the time penalties associated 
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with these processes, as well as reliable data processing and 
display. All of these issues are significantly exacerbated for 
MRSI. We indicate solutions to these issues and provide 
guidance for recommended acquisition and data‐processing 
protocols within the context of current scanner capabilities.
3.1 | Single‐voxel spectroscopy acquisition
Point‐resolved spectroscopy localization is the current stand-
ard for SVS and is commercially available from all scanner 
manufacturers. We recommend a maximum CSD level of 4%/
ppm, in which the percentage relates to the spatial displace-
ment as a proportion of the slice‐selection width. This max-
imum recommended level of CSD is achieved at 1.5 T, but 
exceeded in some implementations at 3 T due to insufficient 
bandwidth of conventional RF pulses resulting from a limited 
maximum transmit field B1max. Increased CSD makes plan-
ning and interpretation of SVS more challenging due to dif-
ferent metabolite signals being localized to different volumes. 
Therefore, methods to reduce CSD, while maintaining good 
SNR, short TEs and accurate localization, should be used to 
achieve the full advantages of clinical MRS at 3 T. One of the 
first approaches to reduce CSD was the use of very selective 
saturation (VSS) pulses that have high bandwidth and can sup-
press an outer‐volume signal with minimal CSD. Conventional 
PRESS is used to excite a larger (approximately 20%) region 
than required, and VSS pulses redefine a smaller region with 
minimal CSD,72,73 a method known as OVERPRESS.
Adiabatic pulses have a substantially greater bandwidth 
(for a given B1max) than the conventional refocusing pulses 
used in the PRESS sequence and were first applied to 3D, 
single shot localized MRS in the SADLOVE sequence,74,75 
and later employed in the closely related LASER sequence.76 
More recently, the semi‐LASER77-79 sequence has been 
developed, replacing the adiabatic excitation pulse of LASER 
with 1 conventional slice‐selective excitation pulse to reduce 
the minimum achievable TE. Higher‐order hyperbolic secant 
adiabatic full passage or gradient‐modulated offset‐indepen-
dent adiabaticity pulses may be used for refocusing in semi‐
LASER, with the latter using wideband, uniform rate and 
smooth truncation RF and gradient waveform modulation.80,81 
The advantage of gradient‐modulated offset‐independent adi-
abaticity pulses compared with hyperbolic secant adiabatic 
full passage is a reduced maximum B1 strength required for a 
given pulse bandwidth, enabling semi‐LASER to be used at 
short TE (~30 ms) on 3T systems with a maximum available 
F I G U R E  6  Illustration of spectral quality maps generated by the MIDAS software package.71 A, T1‐weighted MRI corresponding to the 
selected MRSI slices. B, Raw tNAA signal intensity map. C, Spectral quality map, showing regions that passed the quality criteria for metabolite 
linewidth of 0.1 ppm or less (white). Regions that failed metabolite linewidth‐quality criteria, but passed water‐reference linewidth criteria, are 
shown in light gray. Regions that failed both linewidth criteria are shown in dark gray. C, The tNAA map with the identified poor‐quality voxels set 
to zero. Note the signal dropout in much of the anterior cingulate cortex, related to insufficient shimming close to air–tissue interfaces (e.g., sinuses, 
ear canals). Data were obtained using volumetric (3D echo planar spectroscopic imaging [EPSI]) proton (1H) MRSI with lipid inversion nulling at  
3 T, TE/TR/TI = 17.6/1550/198 ms, 50 × 50 × 18 k‐space points over 280 × 280 × 180 mm3, and total acquisition duration of 16 minutes
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B1 strength of 13‐15 µT.
82 In addition, gradient‐modulated 
offset‐independent adiabaticity semi‐LASER has a reduced 
RF power deposition compared with hyperbolic secant adi-
abatic full‐passage pulses of the same bandwidth, enabling 
the sequence to be used with a shorter TR and at higher field 
strengths within specific absorption rate limits. Although 
adiabatic pulse pairs offer improved resilience to B1 inhomo-
geneity, their primary advantage for SVS at 3 T is increased 
bandwidth and slice‐selection profiles, thereby reducing CSD 
to acceptable levels. A further advantage of semi‐LASER, 
compared with PRESS for the same TE, is longer apparent 
T2 relaxation times and partially suppressed J‐coupling evo-
lution, due to the Carr‐Purcell‐Meiboom‐Gill‐like refocusing 
pulse train (and therefore enhanced detection of complex mul-
tiplets such as glutamate.)79,83
Overall, we recommend the use of semi‐LASER due to 
its recent validation studies84-89 and increasing availabil-
ity on clinical systems, as both research work‐in‐progress 
sequences and commercial product (Figure 2). Furthermore, 
in our consensus survey, semi‐LASER was ranked as the 
most likely localization technique to improve clinical MRS. 
We also recommend the use of PRESS with VSS pulses if 
this is the only option available, but note this option lacks the 
partially suppressed J‐coupling evolution and longer appar-
ent T2 relaxation when compared with semi‐LASER, and can 
inadvertently excite or refocus large signals (e.g., scalp lip-
ids) that are difficult to suppress fully.
In general, we recommend the shortest achievable TE for 
SVS at any field strength, assuming that CSD remains within the 
acceptable range of 4%/ppm and appropriate analysis methods 
are used to model the increased amplitude of macromolecular 
and lipid signals. The advantages of using the shortest possible 
TE include (1) improved SNR due to reduced T2 relaxation, 
(2) more accurate concentration estimation due to a reduced 
dependence on assumed metabolite T2 values, and (3) improved 
SNR for J‐coupled metabolite signals due to reduced dephasing. 
Other TEs may be appropriate for improved detection of spe-
cific metabolites, such as lactate/alanine at a TE of 144 ms or 
TE of 97 ms for 2‐hydroxyglutarate with PRESS.90 Longer TEs 
may also be preferred to improve water and lipid suppression, 
due to their shorter T2 compared with metabolites, or if optimal 
long TE biomarkers are targeted, such as tCho/tCr in glial tumor 
grading.91 A SVS TR of 1.5 seconds at 1.5 T and 2.0 seconds 
at 3 T is recommended to provide the maximum SNR per unit 
time, on average, for the main metabolite signals from tCho, tCr, 
tNAA, and lactate. Further justification and discussion on the 
compromise among TR, SNR, and T1 saturation may be found in 
Supporting Information Figures S3, S4, and Section C).
The recommended number of averages for typical voxel 
dimensions of 15 × 15 × 15 mm3 and 20 × 20 × 20 mm3 
for 1.5 T and 3 T are given in Table 1. A reduction in voxel 
dimensions results in a loss of SNR; therefore, additional 
averages are required to attain suitable quality data. Note that 
SNR scales with the square root of the number of averages. 
Accordingly, an unacceptably long time is required for the 
15‐mm‐sided cubic voxels to attain the same SNR as with the 
20‐mm‐sided cubic voxels; therefore, the recommended aver-
ages represent a compromise that results in an SNR reduction 
T A B L E  1  SVS acquisition consensus summary
Aspect Consensus
Localization method CSD of less than 4% per ppm.
3 T: Semi‐LASER with OVS (preferred) or OVERPRESS with VSS.
1.5 T: Semi‐LASER with OVS (preferred) or PRESS.
TE and TR TE as short as possible (typically 30 ms). Longer TEs may be preferred for lactate (144 ms or 288 ms) at TEs 
optimized for specific metabolites, such as 2HG detection, and for enhanced lipid suppression.
TR = 1.5 seconds at 1.5 T, 2.0 seconds at 3 T.




128 averages collected from a 15 × 15 × 15 mm3 VOI at 3 T.
64 averages from a 20 × 20 × 20 mm3 VOI at 3 T.
256 averages collected from a 15 × 15 × 15 mm3 VOI at 1.5 T.
128 averages from a 20 × 20 × 20 mm3 VOI at 1.5 T.
Spectral sampling of 1024 complex data points from 2000‐Hz spectral width at 1.5 T or 3 T.
Water‐reference 
acquisition
Recommended in all cases. Collect with the same sequence parameters as the water‐suppressed scan, but without water 
suppression and the transmitter frequency set to the water resonance. A single average should be collected with a 
pre‐acquisition delay time of at least 9 seconds to prevent T1 weighting
B0 shimming 
hardware
Second‐order shim coils with adequately powered amplifiers are recommended at 3 T.
B0 shimming 
algorithm
Methods incorporating shim‐strength limits and instability countermeasures are preferred over unconstrained 
approaches.
Abbreviations: 2HG, 2‐hydroxyglutarate; OVS, outer‐volume suppression.
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of 40% for the smaller voxel size. However, because shim-
ming is generally improved for smaller voxel sizes, some sig-
nal loss is mitigated by narrower linewidths.
In addition to water‐suppressed data, which are required 
for metabolite level/concentration estimation, a matched 
unsuppressed water‐reference acquisition (acquired with 
the transmit frequency set to the water resonance) is recom-
mended as part of all SVS clinical protocols. Because the 
water resonance has high SNR compared with metabolites, 
we recommend acquiring a single average for the water‐
suppressed data. When possible, a minimum period of 9 
seconds without RF excitation should be ensured before 
acquisition, to essentially eliminate T1 weighting for water 
in normal and pathological tissue. A 9‐second delay also 
ensures that the T1 saturation signal loss is less than 10% 
in cystic regions or CSF. Dummy scans should be used to 
achieve a steady state in cases in which the recommended 
relaxation period cannot be guaranteed. The water signal 
may be used to correct for eddy current line‐shape dis-
tortions42; estimate B0 field homogeneity and frequency 
offset; evaluate water‐suppression quality; and provide 
metabolite concentration scaling information for use with 
short TE acquisitions.47
3.2 | Magnetic resonance spectroscopy 
imaging acquisition
The MRSI acquisitions excite a much larger volume of tissue 
compared with SVS; therefore, a more stringent maximum 
CSD of 2% per ppm (across the selected volume) is recom-
mended. Any CSD levels greater than 2% per ppm result in a 
significant loss of metabolite information around the edges of 
the MRSI excitation region, making it challenging to obtain 
the required spatial coverage in the cortex, such as avoiding 
unwanted excitation of scalp lipids. It is recommended that 
edge voxels be excluded from the from data analysis. We rec-
ommend the use of semi‐LASER over PRESS for 3T MRSI 
prelocalization, due to its reduced CSD level and additional 
reasons stated in the SVS acquisition section. Where avail-
able, the use of high‐bandwidth spatially selective saturation 
bands92,93 are also recommended to improve conformance 
between the excitation volume and the region of interest by 
suppressing scalp lipid regions that are unavoidably excited 
by the prelocalization scheme. Standard OVS is also recom-
mended for suppressing signals from brain areas with sig-
nificant B0 inhomogeneity (e.g., frontal sinuses), to reduce 
PSF‐related distortion spread. A narrower PSF, resulting 
from acquisition with higher in‐plane resolution, is also rec-
ognized as an effective strategy for reducing scalp lipid con-
tamination—provided that the extra scan time and reduced 
SNR can be tolerated.
For 2D phase‐encoded MRSI, we recommend the use of 
elliptical sampling in k‐space and TRs of 1.5 seconds at 1.5 
T and 2.0 seconds at 3 T (Supporting Information Section C). 
The phase‐encoding FOV should fully encompass the pre-
localization volume to avoid aliasing, and the use of a 16 × 
16 imaging matrix with 10‐mm in‐plane resolution and slice 
thickness of 15 mm is recommended as a default protocol. 
Note that the recommended spatial coverage and resolution 
parameters are intended as a starting point only, and may 
need to be adjusted to match the disease location, extent, and 
clinical question. For instance, in the case of inadequate pre-
localization, the phase‐encoding FOV should be increased to 
contain regions of spurious signals to avoid aliasing. As with 
SVS, short TEs (approximately 30 ms) are recommended for 
MRSI, due to the greater level of metabolite information, 
higher SNR, and reduced T2 bias in concentration estimates. 
However, in areas of greater B0 inhomogeneity, where water 
and lipid suppression are less effective, longer TEs may be 
necessary to reduce water and lipid signals relative to metab-
olites. An unsuppressed MRSI water scan should be acquired 
to aid line‐shape correction, phasing, chemical‐shift refer-
encing, and quantitation. Because an additional MRSI water 
acquisition doubles the effective scan time for MRSI at the 
same spatial resolution (unlike SVS), a reduced resolution 
acquisition or parallel imaging62 approach may be used to 
mitigate the associated time penalty for acquiring the unsup-
pressed water MRSI.
Although 2D phase‐encoded MRSI with prelocalization 
is currently the most commonly used MRSI technique in the 
clinical environment, there is strong interest in the develop-
ment of robust whole‐brain MRSI within a clinically feasible 
acquisition time. In addition to the obvious advantages for 
studying diseases that are known to affect multiple brain areas, 
such as neurodegeneration,94 the ability to plan an MRSI 
acquisition as easily as standard MRI (i.e., without having to 
preselect a region of interest) will improve data consistency 
and acceptance in clinical centers. The use of prelocalization 
also significantly restricts spatial coverage, making it very 
difficult to study cortical regions near to the surface of the 
brain. Using conventional phase encoding, 3D MRSI is only 
practical for limited brain regions when there is the option of 
highly efficient OVS. For instance, the use of VSS pulses73 
or a 3D 8 × 8 × 8 MRSI matrix of 15‐mm isotropic voxels 
provides good quality data in 12.8 minutes for a TR of 1500 
ms and a full k‐space acquisition. For whole‐brain examina-
tion, 3D MRSI is prohibitively time‐consuming; therefore, a 
number of fast acquisition methods have been developed by 
the research community.
The most commonly used whole‐brain MRSI acquisition is 
the echo planar spectroscopic imaging (EPSI) technique,95-97 
in which an oscillating readout gradient generates an echo 
train, encoding a full plane of k‐space for each excitation. 
When applied to the proton nucleus, PEPSI (proton PEPSI) 
is also used to describe the same sequence98; however, we 
generally recommend the use of the more generic term EPSI. 
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The chemical shift and 1 spatial dimension are simultaneously 
encoded during the gradient‐echo readout, and phase encod-
ing is used for the 2 remaining spatial dimensions. Recent 
implementations of EPSI use either whole‐slice/slab acqui-
sition with OVS99,100 or whole‐brain acquisition with lipid 
inversion nulling and postacquisition k‐space extrapolation101 
to significantly reduce scalp lipid contamination. In addition, 
an interleaved water acquisition is used to improve reconstruc-
tion in the presence of B0 inhomogeneity and drift, and to pro-
vide a reference signal for metabolite concentration scaling.102 
Unlike many other MRSI approaches, the whole‐brain 3D 
EPSI sequence has been implemented and tested on instru-
ments from 3 manufacturers with encouraging consistency 
across sites.103 The main advantages of this sequence are 
greater coverage of the cerebrum and simpler planning. This 
sequence has been reported to sample, on average, 70% of the 
brain volume,104 although with instrumentation‐dependent 
differences. Recent 3T studies using whole‐brain 3D EPSI 
have been able to achieve an acquisition time of 18 minutes 
with a TE of 20 ms, which may be acceptable for clinical tri-
als and some specialized clinical assessments.105 Shorter scan 
times are feasible using partial‐brain 3D EPSI.100,106
An alternative approach for whole‐brain MRSI is to com-
bine medium‐resolution EPSI encoding (10‐mm isotropic) 
with OVERPRESS localization and automatically prescribed 
VSS bands.107 This sequence is relatively fast to acquire (13 
minutes) and does not require lipid inversion nulling, which 
also suppresses potentially useful lipid signals originating 
from pathology. In addition, the automated prescription of 
this sequence is much more practical for clinical use when 
compared with manually prescribing PRESS volumes in 
combination with saturation pulses and shim volumes. This 
approach has been tested on a clinical cohort of brain tumor 
patients with encouraging results.107
Considerable progress toward robust whole‐brain MRSI 
has been made in recent years, and a wide range of techniques 
has been demonstrated to provide high acceleration.106,108 
At the time of writing, we were unable to recommend one 
whole‐brain MRSI approach over another, and identified a 
need for comparative studies to assess the relative perfor-
mance of the various approaches.
3.3 | Single‐voxel spectroscopy and MRSI 
preprocessing and analysis
Fully automated analysis methods, which perform phase cor-
rection, chemical shift calibration and quantitative analysis of 
metabolite signals, have been available for 25 years32 and are 
strongly recommended for MRS analysis. A choice of commer-
cially licensed (LCModel32), free (jMRUI109), and open‐source 
(e.g., TARQUIN,35 MIDAS,71 SIVIC,110 VeSPA [http://scion.
duhs.duke.edu/vespa/]) software packages have been devel-
oped, predominantly by the research community, and are 
available for offline data visualization and analysis. Analysis 
methods available on the scanner software are typically inferior 
to those used in dedicated software packages, and an improve-
ment in this area would greatly benefit clinical MRS. There is 
currently no clear consensus on the best analysis algorithm for 
use in all cases; however, a common feature of the most widely 
used methods is the use of a quantum mechanically simulated 
set of metabolite spectra (basis set) into the fitting routine. 
Modeled lipid signals and modeled or measured macromolecu-
lar signals can be included in the basis set when appropriate 
(e.g., short TE protocols or investigations of pathologies with 
hypoxic/necrotic processes such as stroke and tumors).
The jMRUI, TARQUIN, and VeSPA packages have metab-
olite basis simulation integrated into the analysis software. In 
the case of jMRUI, metabolite simulation is performed using 
the NMRSCOPE‐B111 method and VeSPA makes use of the 
GAMMA library.112 The FID‐A package also provides tools 
to simulate metabolite basis sets, in addition to preprocessing 
steps and data export options for fitting to be performed with 
other software.113 We recommend the use of analysis meth-
ods based on fitting with simulated metabolite basis sets over 
single‐peak modeling or spectral integration, as simulated 
basis sets conveniently incorporate a greater level of prior 
knowledge38,41 into the fitting process, which can easily be 
adapted to match the acquisition protocol.
Quality assessment must be an integral part of MRS anal-
yses, as distorted or poorly fit data leads directly to erroneous 
results. Metabolite SNR and linewidth estimates are recom-
mended as objective measures of data quality. A number 
of spectral SNR definitions have been described for MRS. 
Here, we recommend that the signal measure be defined as 
the height of the largest metabolite data point in the real part 
of the spectrum minus the fitted baseline at that point; and the 
noise measure as 2 times the SD of the spectral data points in 
a region free from metabolite signals, residual water, or other 
spectral distortions. Although other measures of spectral 
SNR are acceptable, reported values should be accompanied 
by a definition to avoid ambiguity; for example, the current 
version of the LCModel32 analysis package defines the noise 
as 2 times the SD of the fit residual. Linewidth estimates 
(FWHM) are also usually measured, in units of hertz or parts 
per million, from the real part of the phased spectrum and are 
typically derived from the most prominent singlet metabolite 
or unsuppressed water resonance. Although universal guide-
lines for acceptable MRS data quality are challenging, due to 
the heterogeneous metabolite profiles of diseases and wide 
range of acquisition protocols, spectra with FWHM greater 
than 0.1 ppm should be regarded as being of poor quality. A 
minimum metabolite SNR of 3 is recommended to confirm 
the presence of a particular singlet; however, greater metab-
olite SNR values are required for accurate quantification or 
detection of coupled multiplets. Sample spectra with differ-
ent SNR and FWHM values are shown in Figure 7.
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Although SNR and linewidth criteria are useful for basic 
quality assessment, a visual inspection of fitting results remains 
important, as analysis errors and data artifacts may produce 
unrealistic values. Furthermore, these values do not reliably 
detect a number of quality issues such as unstable or unrealistic 
baseline estimates during fitting or out‐of‐volume lipid contam-
ination. To aid visual assessment, we recommend that the anal-
ysis output include plots of the phased spectra with the fit and 
estimated baseline and residual for retrospective visual assess-
ment of the data (example given in Figure 1 with the optional 
addition of individual basis signals). For SVS, a quick visual 
assessment of the data and fit quality can easily be performed 
by someone with a basic understanding of MRS and common 
artifacts,43 and this approach is suitable for the clinical envi-
ronment. However, for MRSI, where hundreds of spectra are 
typically acquired in a single scan, visual assessment is often 
impractical and there is great interest in developing automated 
quality assessment. One of the first approaches, based on the 
classification of independent spectral components, was found 
to provide 87% agreement with expert spectroscopic evalua-
tions.70 More recently, methods based on random forest classi-
fication of spectral data69 and features extracted from the time 
and frequency domain114 have also been shown to provide high 
agreement with expert assessment. Although these techniques 
are an important step toward fully automated MRS quality con-
trol, their applicability across different scanners, experimental 
protocols, and clinical scenarios requires further investigation.
Before SVS fitting, eddy‐current correction using the 
unsuppressed water reference is recommended to reduce 
metabolite signal line‐shape distortions.42 There is also an 
increasing trend toward retrospective frequency and phase 
correction of each average and elimination of motion‐ 
corrupted FIDs prior to signal averaging.115-117 Although 
these methods have been successfully applied to scans with 
high metabolite signal (e.g., normal appearing brain), their 
suitability for low‐SNR clinical spectra (e.g., brain tumors) 
has not been fully investigated and therefore should be 
used with caution. We also note the promising approach 
of using “metabolite‐cycled” MRS for retrospective cor-
rection using the water signal, allowing low‐SNR spectra 
to be accurately corrected, while maintaining metabolite 
spectral quality.118
The analysis pipeline for MRSI includes preprocessing 
steps to aid interpretation. K‐space filtering with a suit-
able window function, such as Hamming, is recommended 
for reducing distortions from Gibbs ringing of high‐inten-
sity signals such as scalp lipids. Fourier interpolation, by 
k‐space zero filling, to twice the acquired dimensions is 
also recommended to aid display and interpretation of 
metabolite maps. Optimized reconstruction methods, such 
as the Papoulis‐Gerchberg algorithm, are also recom-
mended to reduce lipid artifacts.101 More recently, a variety 
of novel reconstruction methods were shown to suppress 
MRSI lipid signals119-122 with promising initial results, but 
F I G U R E  7  Simulated “normal brain” spectra for a typical PRESS acquisition at 3 T (TE = 30 ms, 1024 data points, and 2000‐Hz sampling 
frequency). The SNR and FWHM values are given for the largest singlet resonance (tNAA)
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validation on clinical data is required before recommend-
ing them for general use.
3.4 | B0 inhomogeneity and water 
suppression
The current generation of commercially available shimming 
and water‐suppression algorithms does not provide the reli-
ability and robustness needed for performing MRS/MRSI at all 
locations in the brain. In addition to being quite time‐consum-
ing, these drawbacks are important impediments to the wider 
clinical use of MRS. Therefore, we encourage the research com-
munity and MR vendors to optimize the performance of shim-
ming, water suppression, and power‐calibration steps in both 
favorable and challenging brain regions.
Both projection (FASTMAP and variants) and volumetric 
mapping acquisition methods are widely available, and can be 
effective for B0 shimming, with projection methods generally 
taking less time. A recent study demonstrated that FASTMAP 
linewidths were 40% better than a vendor implementation of 
volumetric mapping for an 8‐mL SVS VOI in the posterior 
cingulate cortex.85 We note that the vendor implementation 
of volumetric mapping has since been updated and improved, 
highlighting the challenges of comparing shimming method-
ology: Seemingly minor implementation differences often 
have a significant effect on the overall performance of a par-
ticular strategy.
Although volumetric mapping methods are thought to be 
better suited for large VOIs typical to MRSI, no systematic 
studies have been published by the time of this writing that 
test this assertion. In addition to the B0 mapping strategy, the 
shimming optimization method is crucial for automated and 
reliable shimming, and a number of algorithms have been 
published and recently compared.123 Improved performance 
was found for methods incorporating known constraints on 
the maximum available shim strengths and mitigation for 
instability; therefore, these types of methods are recom-
mended over simpler unconstrained algorithms.
Adequate hardware is essential for good B0 homogeneity, 
and second‐order shim coils are recommended for MRS of 
acceptable quality, particularly at 3 T. In addition, adequately 
powered shim amplifiers are important to ensure good‐qual-
ity data in anatomic regions such as the hippocampus and 
frontal brain regions, where there are large susceptibility 
gradients.
Our recommendations for second‐order shimming hard-
ware, combined with accurate B0 field mapping and robust 
shimming optimization methods, enable the acquisition of 
SVS with acceptable spectral quality throughout the brain 
at 3 T. However, for whole‐brain MRSI techniques, such 
as 3D EPSI, the requirement for homogeneous B0 across 
all brain regions simultaneously cannot be achieved with 
second‐order shim coils. Figure 6 illustrates how poor B0 
homogeneity results in unusable spectra in the anterior cin-
gulate cortex when using 3D EPSI, therefore restricting the 
use of MRS in this region to 2D MRSI or SVS techniques. 
Homogeneous B0 across the whole brain is also desirable for 
gradient‐echo EPI, and particularly challenging at ultrahigh 
field (7 T and above), resulting in the development of a num-
ber of novel shimming approaches.124,125 Although these 
methods show great potential for improving MRS, at both 
low and high field, it is currently unclear which will provide 
the best balance among patient comfort, cost, and efficacy.
3.5 | Data formats and interoperability
The MRS results and data may be exported from the scan-
ner console in the following formats: (1) DICOM MRS, (2) 
DICOM secondary capture, and (3) data points stored in a 
proprietary format. The DICOM secondary captures (or 
“screenshots”) typically store an image of the spectrum and 
fit, alongside the voxel location and quantitative measures, 
such as metabolite ratios. For MRSI, metabolite maps are 
also generally displayed together with relevant MRI scans. 
Although secondary captures are essential for rapid clini-
cal interpretation, they do not allow re‐analysis or interac-
tive inspection of the data, which is particularly important 
for MRSI. For example, following an initial analysis, it may 
become clear that a brain region has an abnormal metabolite 
profile that is consistent with a brain tumor; therefore, a re‐
analysis is required using a cancer‐specific metabolite ratio 
map with a basis set containing additional metabolites, or it 
may be advisable to re‐inspect the spectral quality in crucial 
areas.
Storage of the acquired complex MRS data points, either 
in the time or frequency domain, is essential to ensure the 
extraction of maximal information. Historically, each ven-
dor had 1 or more proprietary formats for exporting raw data 
files—primarily for offline analysis with third‐party tools 
such as LCModel.32 However, proprietary formats have the 
following disadvantages: (1) They require extra time and 
computing resources to generate and securely archive, partic-
ularly when a hospital contains multiple scanners from differ-
ent vendors; 2) patient details may not be stored in a way that 
allows the reliable identification of files, creating problems 
for comparing scans obtained from multiple sites/scanners 
and effective de‐identification—often a requirement for clin-
ical trials; and (3) additional burden is placed on researchers 
and third‐party software developers to support the file for-
mats, which often change with software updates.
To address these issues, the DICOM standards com-
mittee introduced Supplement 49 “Enhanced MR Image 
Storage SOP Class” in 2002, which included the “MR 
Spectroscopy Information Object Definition” that is suit-
able for the storage and transfer of MRS data. This allows 
MRS data points, and associated localization volume 
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and acquisition information, to be archived to the picture 
archiving and communication system alongside the MRI, 
using a local network and the same protocols and infrastruc-
ture in place as in most radiology departments. Therefore, 
we recommend the use of the DICOM standard for storage 
and network transmission of the MRS data points and anal-
ysis results from the scanner, and strongly encourage MR 
and picture archiving and communication system vendors 
to implement the standard. For SVS, the storage of individ-
ual averages is recommended to aid retrospective correction 
of frequency and phase instabilities and the identification/
removal of motion‐corrupted averages. Standard DICOM 
tags should be used to store all important sequence and 
localization information, and the use of private tags for this 
information is strongly discouraged, as private tags cannot 
be guaranteed to be free from protected health information 
and are therefore automatically removed as part of the de‐
identification procedures required for clinical trials.
Although the DICOM‐MRS format is essential for clini-
cal purposes, we also recognize the importance of “raw” data 
formats. For instance, the data from each coil element need 
to be stored separately for researchers to develop and com-
pare reconstruction methods, and the DICOM format may 
not be suitable for these purposes. For these, reconstruction 
research–orientated application formats, such as the ISMRM 
raw data format, are recommended for data export.126
3.6 | Reporting
The ideal for using MRS as a clinical biomarker would be the 
ability to report tissue metabolite levels fully, quantitatively, 
and independent of the scanner type or the pathology under 
investigation. In practice, limitations of SNR include the 
need for reasonable acquisition times, the need for voxels to 
contain mixed tissue types of variable relaxation times, and 
the effects of methodological variations due to differences 
in scanner software and hardware; these restrict convergence 
to the ideal. In addition, there may be reluctance to move 
too far away from a specific institutional MRS protocol and 
acquire new data that are no longer comparable to historical 
studies. Hence, pragmatically, our recommendations balance 
limited protocol variability with best practices of acquiring 
high‐quality MRS data, avoiding a methodology that leads to 
extreme variation in MRS characteristics. Nevertheless, the 
appearance of the spectrum may still have characteristics that 
depend on the acquisition protocol, and the subsequent data 
processing may lead to further differences—all of which may 
affect visual or pattern recognition analyses. The most prom-
ising clinical applications for MRS have been described,1 but 
further work is needed for the development of standardized 
MRS biomarkers that enable rigorous and robust multi‐insti-
tutional use. Hence, it is essential that key details be provided 
in MRS publications to enable appropriate comparisons 
among different studies and for meta‐analyses, to better 
assess the efficacy of the proposed MRS biomarkers.
At the 2016 ISMRM workshop “MR Spectroscopy: From 
Current Best Practice to Latest Frontiers,” attendees were 
asked to comment on a set of minimum and recommended 
requirements for the reporting of MRS studies. Level 1 
requirements were the parameters that are considered the 
minimum for proper and correct reporting of MRS stud-
ies by more than 80% of the attendees. Parameters that had 
between 40% and 80% support as relevant for inclusion in 
MRS reporting are ascribed as level 2. A detailed consensus 
on MRS reporting is currently being developed for an NMR 
in Biomedicine Special Issue (expected publication in late 
2019); hence, only the outline of level 1 minimum require-
ments is included here (Supporting Information Section D) in 
relation to our consensus on 1H MRS of the brain.
4 |  SUMMARY AND 
CONCLUSIONS
Tables 1, 2, and 3 summarize SVS, 2D MRSI, and analysis/
interpretation recommendations, respectively. To facilitate 
greater clinical utility of MRS, we encourage vendors to 
implement all recommendations as outlined here. We high-
light the following 3 recommendations as being likely to 
have the greatest importance for improving routine clinical 
MRS and achieving reliable MRS results:
1. Implementation of a robust semi‐LASER protocol to 
improve the localization of SVS and MRSI at 3 T;
2. Incorporation of simulated metabolite, lipid, and macro-
molecular basis sets in spectral analyses for more robust 
extraction of the maximum amount of metabolic informa-
tion available; and
3. Use of optimized algorithms to perform time‐efficient, 
robust, and high‐quality automated shimming.123
These highlighted recommendations are all software‐
based and can therefore be implemented on almost all exist-
ing clinical scanners, significantly enhancing their MRS 
capabilities.
Although we have intentionally restricted the scope of our 
recommendations to the most common clinical field strengths 
of 1.5 T and 3 T, the same recommendations are also relevant to 
ultrahigh field (7 T and above), where reducing CSD and imple-
menting robust shimming present significantly greater chal-
lenges.127 Furthermore, a greater number of metabolites can be 
detected reliably at ultrahigh field, due to wider chemical shift 
dispersion, and the use of comprehensive simulated metabolite 
basis sets is required to capture the full metabolite profile.128
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Consensus on appropriate experimental methodol-
ogy is an evolving process, and we emphasize that this 
paper should not represent the final word on the topic. 
Our intention is to provide an assessment of the current 
state‐of‐the‐art and recommend improvements to MRS 
methodology and standardization, with a strong focus on 
clinical applications. However, variety is essential for fruit-
ful developments of new and alternative methods, yielding 
the clinical workhorses of the future. A current initiative 
will produce a special issue that will expand on this paper 
with a greater focus on ultrahigh‐field MRS and more 
novel methods.
T A B L E  2  Two‐dimensional MRSI acquisition and preprocessing consensus summary
Aspect Consensus
Prelocalization method CSD less than 2% per ppm.
3 T: Semi‐LASER with OVS (preferred) or OVERPRESS with VSS.
1.5 T: Semi‐LASER with OVS (preferred) or PRESS with VSS.
TE and TR TE as short as possible (typically 30 ms). Longer TEs may be preferred for lactate detection (144 
ns or 288 ms) and enhanced lipid suppression.
TR = 1.5 seconds at 1.5 T, 2.0 seconds at 3 T.
Matrix dimensions, nominal voxel 
dimensions, and sampling parameters
16 × 16 matrix with 10‐mm in‐plane resolution and 15‐mm slice thickness; 1 average per 
phase‐encoding step.
Spectral sampling of 1024 complex data points at 2000‐Hz spectral width at 1.5 T or 3 T.
k‐space sampling and preprocessing 2D phase‐encoded Cartesian sampling over an elliptical or circular k‐space mask.
K‐space zero‐filling (interpolation) to twice the acquired number of points.
Hamming filter.
Reduction of subcutaneous lipid contamination (e.g., Papoulis‐Gerchberg algorithm).
Water‐reference acquisition Should be acquired where possible. Collect with the same sequence parameters as the water‐sup-
pressed scan, but without water suppression. Typically, to reduce scan time, a lower resolution 
scan is acceptable and interpolated following acquisition to match the metabolite resolution.
B0 shimming hardware Second‐order shim coils with adequately powered amplifiers are recommended at 1.5 T and 3 T.
B0 shimming algorithm Methods incorporating shim strength limits and instability countermeasures are preferred over 
unconstrained approaches.




Time‐domain apodization (line broadening) and zero‐filling steps should not be applied before spectral fitting, although 
may aid visual interpretation. Water reference–based eddy‐current correction42 before fitting is recommended where 
possible.
Analysis methods Methods should be fully automated, performing phasing, chemical shift calibration, and metabolite amplitude estimation 
without user intervention.
The flexibility to be able to model typical baseline and linewidth variations is an essential requirement, which may be 
achieved using time or frequency‐domain approaches.
Basis set Methods that incorporate prior knowledge using a basis set are recommended over spectral integration or simple fitting 
of independent single peaks.
Metabolite basis sets simulated from known J‐coupling and chemical‐shift values to match the acquisition protocol are 
recommended for analysis.
Lipid basis signals should also be incorporated for tumor analysis and macromolecule signals for short‐TE (< 80 ms) 
analyses.
Quality assessment Single‐peak metabolite and, where available, water linewidths should be measured at half height (FWHM) as part of an 
automated analysis pipeline.
Metabolite or water linewidths less than 0.1 ppm are required for accurate analysis, and a metabolite SNR greater than 3 
is the minimum criterion for determining the presence of a singlet.
Visual assessment of spectral and fit quality is recommended, based on the combined display of the phased spectrum, fit, 
estimated baseline, and fit residual.
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In conclusion, a large body of research demonstrates 
that (1) robust, high‐quality MRS data may be acquired 
with the hardware available on current clinical MR sys-
tems; and (2) many technical challenges of performing 
clinically useful SVS and MRSI at 1.5 T and 3 T can be 
overcome with software improvements applied to current 
scanner hardware. In this consensus paper, a series of 
methodological recommendations have been made to pro-
vide a degree of standardization and equivalency of meth-
odology across all scanner platforms, and guidelines have 
been drawn up on the current best practices for clinical 
MRS.
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FIGURE S1 A selection of example spectra demonstrat-
ing the following features: good shimming (A), acceptable 
shimming (B), poor shimming and water suppression (C), 
out‐of‐volume lipid contamination (D), “ghost” artifact (E), 
and very poor shimming and water suppression (F). Further 
examples of poor spectra may be found in Refs 43 and 129
FIGURE S2 Single‐voxel spectroscopy planning with mod-
erate CSD. Incorrect (A) and improved (C) voxel planning 
by reversal of the gradient polarity in the left–right direction; 
corresponding spectra are shown in (B) and (D). Lipid and 
metabolite excitation regions are shown in cream and orange, 
respectively
FIGURE S3 The effect of TR on the SNR per unit time due 
to T1 saturation relative to that at TR = 6000 ms. On average, 
across the 4 metabolite curves shown, the maximum SNR 
per unit time is close to 1500 ms at 1.5 T and 2000 ms at 3 
T. The metabolite T1 values used are the average values from 
different normal brain regions acquired with exactly the same 
acquisition and processing protocols at both 1.5 T and 3 T: 
tCho = 1103/1290 ms; tCr = 1232/1375 ms; and tNAA = 
1303/1482 ms.130 A lactate T1 of 2000 ms at 3 T for high‐
grade gliomas was used,131 and this value scaled to 1754 ms 
for 1.5 T using a factor of 1.14, the average ratio of the nor-
mal‐tissue metabolite T1 values at the 2 field strengths
FIGURE S4 Effect of T1 saturation on tissue water signals 
and main metabolite signals and clinically relevant metab-
olite ratios. A TR of 6000 ms is required to maintain the 
signals shown within 95% of their unsaturated values. At 
1.5 T, the T1 values of 3 key metabolites and gray matter 
are similar, and although they are more dispersed at 3 T, 
they have less variability than that for tissue‐water T1. Apart 
from lactate, the saturation curves for signal from patho-
logical tissues are not shown, but pathological tissue with 
increased water content could have a water‐saturation curve 
that is similar to that of lactate (see text for discussion on 
metabolite T1 values in pathological tissue). Tissue‐water 
T1 relaxation times used for 1.5 T/3 T calculations were 
white matter = 650/840 ms; gray matter = 1200/1600 
ms.132 Metabolite T1 values were those used in Supporting 
Information Figure S3
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